Glenmark Pharma surges despite reporting 57% fall in Q2 consolidated net profit
Glenmark Pharmaceuticals is currently trading at Rs. 2648.90, up by 163.40 points or 6.57% from its previous closing of Rs. 2485.50 on the BSE.
The scrip opened at Rs. 2375.00 and has touched a high and low of Rs. 2648.90 and Rs. 2375.00 respectively. So far 154429 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2,683.55 on 06-Nov-2026 and a 52 week low of Rs. 1800.00 on 07-Nov-2025.
Last one week high and low of the scrip stood at Rs. 2,683.55 and Rs. 2,304.70 respectively. The current market cap of the company is Rs. 74196.87 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.19% and 14.17% respectively.
Glenmark Pharmaceuticals has reported net profit at Rs 434.89 crore for the second quarter ended September 30, 2026 (Q2FY27) as compared to net loss of Rs 739.19 crore for the same quarter in the previous year. The total income of the company has increased by 41.63% at Rs 2,584.01 crore for Q2FY27 as compared to Rs 1,824.42 crore for the corresponding quarter of the previous year.
On consolidated basis, the company has reported 56.78% fall in its net profit at Rs 263.78 crore for the quarter ended September 30, 2026 as compared to Rs 610.35 crore for the same quarter in the previous year. The total income of the company decreased by 31.97% at Rs 4,249.87 crore for Q2FY27 as compared to Rs 6,247.50 crore for the corresponding quarter previous year.
